Feb 17, 2022 / 01:00PM GMT
Beth Feindt-Scott - SVB Leerink - Analyst
Good morning, everyone. Thank you so much for tuning in for today's fireside chat with Mereo BioPharma as part of the SVB Leerink Global Healthcare Conference. My name is Beth Feindt-Scott; I'm an associate representing SVB's rare disease team. And it's my pleasure today to introduce Mereo's Denise Scots-King (sic - Denise Scots-Knight), CEO; Christine Fox, CFO; John Lewicki, CSO; Jackie Parkin, SVP and Therapeutic Head; and Suba Krishnan, SVP of Clinical Development.
Before we get started, I did want to let the audience know, if you have any questions, you can feel free to write those in at the chat box at the bottom of your screen and I'll be sure to get to that. And with that we can kick off.
Questions and Answers:
Beth Feindt-Scott - SVB Leerink - AnalystThe first question I have for you guys is I was wondering if you could maybe just start off by giving us an overview of your recent progress, your priorities for the next 12 months and any sort of key catalyst you
Trustpilot
